Literature DB >> 2167738

The action of diazoxide and minoxidil sulphate on rat blood vessels: a comparison with cromakalim.

D T Newgreen1, K M Bray, A D McHarg, A H Weston, S Duty, B S Brown, P B Kay, G Edwards, J Longmore, J S Southerton.   

Abstract

1. The actions of diazoxide and minoxidil sulphate have been compared with those of cromakalim in rat aorta and portal vein. 2. Diazoxide and minoxidil sulphate hyperpolarized the rat portal vein in a similar manner to cromakalim. 3. Cromakalim, diazoxide and minoxidil sulphate increased 42K and 86Rb efflux from rat portal vein, although minoxidil sulphate had only a small effect on 86Rb efflux. 4. Cromakalim, diazoxide and minoxidil sulphate increased 42K efflux from rat aorta but only cromakalim and diazoxide increased 86Rb efflux from this tissue. 5. Glibenclamide inhibited the relaxant actions of cromakalim, diazoxide and minoxidil sulphate on rat aorta and the increase in 42K efflux produced by these agents in this tissue. 6. Diazoxide relaxed an 80 mM KCl-induced contraction of rat aorta, whilst cromakalim and minoxidil sulphate were without effect. 7. Cromakalim, diazoxide and minoxidil sulphate had no effect on cyclic AMP or cyclic GMP concentrations in rat aorta. 8. It is concluded that diazoxide and minoxidil sulphate like cromakalim exhibit K+ channel opening properties in vascular smooth muscle. Diazoxide exerts an additional inhibitory action not related to the production of cyclic AMP or cyclic GMP. The action of minoxidil sulphate may be primarily located at a K+ channel which is relatively impermeable to 86Rb.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2167738      PMCID: PMC1917770          DOI: 10.1111/j.1476-5381.1990.tb15854.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

1.  Pharmacology of diazoxide, an antihypertensive, nondiuretic benzothiadiazine.

Authors:  A A RUBIN; F E ROTH; R M TAYLOR; H ROSENKILDE
Journal:  J Pharmacol Exp Ther       Date:  1962-06       Impact factor: 4.030

2.  Effects of high K on relaxation produced by drugs in the guinea-pig tracheal muscle.

Authors:  M Ito; K Baba; K Takagi; T Satake; T Tomita
Journal:  Respir Physiol       Date:  1985-07

3.  Reversal of diazoxide effects by tolbutamide.

Authors:  J K Wales; A M Grant; F W Wolff
Journal:  Lancet       Date:  1967-05-27       Impact factor: 79.321

4.  The action of diazoxide on isolated vascular smooth muscle electrophysiology and contraction.

Authors:  H J Rhodes; M C Sutter
Journal:  Can J Physiol Pharmacol       Date:  1971-04       Impact factor: 2.273

5.  Opposite effects of tolbutamide and diazoxide on 86Rb+ fluxes and membrane potential in pancreatic B cells.

Authors:  J C Henquin; H P Meissner
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

6.  Sulfation of minoxidil by liver sulfotransferase.

Authors:  G A Johnson; K J Barsuhn; J M McCall
Journal:  Biochem Pharmacol       Date:  1982-09-15       Impact factor: 5.858

7.  Electrophysiological and other aspects of the relaxant action of isoprenaline in guinea-pig isolated trachealis.

Authors:  S L Allen; D J Beech; R W Foster; G P Morgan; R C Small
Journal:  Br J Pharmacol       Date:  1985-12       Impact factor: 8.739

8.  Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75).

Authors:  S Holzmann
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

9.  Effects of some vasodilators on calcium translocation in intact and fractionated vascular smooth muscle.

Authors:  S Thorens; G Haeusler
Journal:  Eur J Pharmacol       Date:  1979-02-15       Impact factor: 4.432

10.  Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein.

Authors:  T C Hamilton; S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

View more
  28 in total

Review 1.  Potassium channel openers. Pharmacological effects and future uses.

Authors:  S Duty; A H Weston
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

Review 2.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

3.  Cyclosporin A does not possess K+ channel opening properties in smooth muscle.

Authors:  B D Edwards; F W Ballardie; M Miller; A H Weston
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

4.  Differential inhibition by tedisamil (KC 8857) and glibenclamide of the responses to cromakalim and minoxidil sulphate in rat isolated aorta.

Authors:  K Bray; U Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

5.  Some degree of overlap exists between the K(+)-channels opened by cromakalim and those opened by minoxidil sulphate in rat isolated aorta.

Authors:  K Bray; U Quast
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-09       Impact factor: 3.000

Review 6.  Pharmacology of the potassium channel openers.

Authors:  G Edwards; A H Weston
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

7.  Antagonism of relaxin by glibenclamide in the uterus of the rat in vivo.

Authors:  S J Downing; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide.

Authors:  S Obayashi; T Aso; J Sato; H Hamasaki; H Azuma
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

9.  Effects of rubidium on responses to potassium channel openers in rat isolated aorta.

Authors:  I A Greenwood; A H Weston
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

10.  The countering of diazoxide-induced vasodilatation by tenoxicam in normal volunteers.

Authors:  D K Sommers; M van Wyk; J R Snyman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.